Regenxbio Inc (RGNX)
Return on assets (ROA)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | -263,494 | -260,540 | -274,156 | -270,274 | -280,321 | 73,637 | 90,716 | 101,256 | 127,840 | -212,424 | -145,228 | -121,351 | -111,250 | -91,473 | -134,848 | -102,543 | -94,733 | -63,963 | -48,581 | -36,530 |
Total assets | US$ in thousands | 573,970 | 633,786 | 682,458 | 747,830 | 833,268 | 883,793 | 953,444 | 1,025,370 | 1,113,900 | 800,395 | 836,402 | 879,442 | 708,164 | 541,174 | 449,738 | 463,936 | 497,908 | 509,237 | 529,139 | 519,031 |
ROA | -45.91% | -41.11% | -40.17% | -36.14% | -33.64% | 8.33% | 9.51% | 9.88% | 11.48% | -26.54% | -17.36% | -13.80% | -15.71% | -16.90% | -29.98% | -22.10% | -19.03% | -12.56% | -9.18% | -7.04% |
December 31, 2023 calculation
ROA = Net income (ttm) ÷ Total assets
= $-263,494K ÷ $573,970K
= -45.91%
Based on the ROA figures provided for Regenxbio Inc for the past eight quarters, the return on assets has shown significant fluctuations. The ROA has been mostly negative over the last five quarters, ranging from -45.91% in Q4 2023 to -33.64% in Q4 2022. This indicates that the company's net income generated by its assets has been insufficient to cover its total assets during these periods.
The negative trend in ROA suggests that Regenxbio Inc may be experiencing challenges in generating profits relative to the size of its asset base. The declining ROA from Q1 2022 to Q4 2023 indicates a deterioration in the company's ability to generate earnings from its assets over the past year. The positive ROA in Q3 and Q2 2022 at 8.33% and 9.51%, respectively, could be seen as outliers in an otherwise negative trend.
This downward trend in ROA raises concerns about the company's operational efficiency and profitability. Investors and stakeholders may be closely monitoring Regenxbio Inc's strategies and financial performance to assess how effectively the company is utilizing its assets to generate returns in the future.
Peer comparison
Dec 31, 2023